Quantifying the Patient Experience: A Systematic Review of JAK Inhibitor Impact on Symptom Scores, Health-Related Quality of Life, and Sleep in Myelofibrosis (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-1147; Location: LEVEL 3, HALL B3; "JAK inhibitors (ruxolitinib, fedratinib, pacritinib, and momelotinib) are approved for MF, yet a quantitative synthesis of their effects on symptom burden and sleep disturbance remains absent. JAK inhibitor therapy produces significant, clinically meaningful reductions in symptom burden, fatigue, night sweats, and HRQoL impairment in patients with MF. Sleep disturbance improvement is supported by indirect evidence from the EORTC QLQ-C30 insomnia subscale and night sweats resolution, although the absence of dedicated sleep instruments limits certainty (Grading of Recommendations, Assessment, Development, and Evaluation: very low for sleep domain). Future MF trials should incorporate validated sleep-specific measures such as the Pittsburgh Sleep Quality Index to directly address this evidence gap."
Clinical • HEOR • Review • Myelofibrosis • Myeloproliferative Neoplasm • Oncology
|
|
Ajina Joy MBBS 1; Basil Joy MBBS 1; Calvin Jose MD 2
|